[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637088":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":50,"collaborators":11,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":11,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Candid Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cizutamig","EXPERIMENTAL",null,[13],"Drug: Cizutamig will be dosed according to the protocol.",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Cizutamig will be dosed according to the protocol.","CND106",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Martin Zhuang","CONTACT","+86 13918519658","martin@candidrx.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Shanghai Ninth People's hospital Shanghai Jiaotong University school of medicines","RECRUITING","Shanghai","Shanghai Municipality","200011","China","CN",{"type":36,"coordinates":37},"Point",[38,39],121.45806,31.22222,{"lat":39,"lon":38},[42,46],{"name":43,"role":23,"phone":44,"phoneExt":11,"email":45},"Huifang Zhou, Ph.D","+86 13661901886","fangzzfang@sjtu.edu.cn",{"name":47,"role":23,"phone":48,"phoneExt":11,"email":49},"Lina Xing, Ph.D","+86 13918035850","jygcp666@126.com",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100637088","phase-1-a-clinical-study-of-cizutamig-in-thyroid-eye-disease-100637088",false,"NCT07597200","A Clinical Study of Cizutamig in Thyroid Eye Disease","A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients With Thyroid Eye Disease","Inclusion Criteria:\n\n* 18-75 years old at the time of signing the Informed Consent Form\n* Diagnosis of Graves' Disease with active, moderate to severe TED in accordance with the Chinese Guidelines for the Diagnosis and Treatment of Thyroid-Associated Ophthalmology (2022) at Screening and Day 1\n\nExclusion Criteria:\n\n* Inadequate clinical laboratory parameters at Screening\n* Active infection present\n* Receipt of, or inability to discontinue, any of the excluded therapies\n* History of progressive multifocal leukoencephalopathy\n* History of primary immunodeficiency\n* Central nervous system disorders that the investigator considers would increase risk to the subject\n* Investigator-determined significant comorbidity(ies)\n* Have a diagnosis or history of malignant disease within 5 years prior to Screening\n* Active tuberculosis or lack of documentation of completed treatment for active pulmonary tuberculosis\n* History of severe allergic or anaphylactic reactions to mAb therapy (or recombinant antibody-related fusion proteins) or any constituents of cizutamig\n* Pregnant or breastfeeding women\n* Patients who do not agree to use highly effective contraception as specified in the protocol","ALL","18 Years","75 Years",{"count":63,"type":64},38,"ESTIMATED","INTERVENTIONAL",[67],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with thyroid eye disease (TED).",[70],"Thyroid Eye Disease, TED","2026-05-13",{"date":73,"type":74},"2026-05-19","ACTUAL",{"date":76,"type":74},"2026-05-08",{"date":78,"type":64},"2028-06-30",{"name":5,"class":6},1]